Candel Therapeutics (CADL) Canaccord Genuity's 46th Annual Growth Conference summary

Company and pipeline overview

• Focuses on off-the-shelf viral immunotherapies for local delivery and systemic immunization.

• Lead asset aglatimagene (CAN-2409) is a replication-defective adenovirus delivering thymidine kinase, targeting localized prostate cancer and non-small cell lung cancer.

• Linoserpaturev (CAN-3110) is a first-in-class oncolytic virus modified to replicate in nestin-expressing tumor cells, developed for brain cancer.

• Both assets have received Fast Track and other FDA designations, with aglatimagene also under SPA and RMAT.

Clinical trial results and regulatory progress

• Phase III trial of aglatimagene in prostate cancer showed a 30% reduction in disease-free survival risk versus standard care.

• Positive feedback from FDA, with BLA submission targeted by year-end; manufacturing scale-up and comparability studies are nearly complete.

• Linoserpaturev has Fast Track and Orphan Drug Designation for brain cancer.

• Phase II data in non-small cell lung cancer showed median overall survival up to 24.5 months in non-squamous patients.

Upcoming data and mechanistic insights

• Upcoming ASTRO 2026 presentation will detail AI-enabled digital pathology analysis of two-year post-treatment biopsies in prostate cancer.

• Data show increased pathological complete response (80% vs 63%) and immune cell engagement at tumor sites.

• Evidence of systemic immune response and abscopal effect in non-small cell lung cancer, with regression of non-injected lesions.

• Linoserpaturev demonstrated strong local and systemic immune activation in glioma, with some patients surviving over 49 months.